Plus, two more picks for a “youthful appearance.” ...

By John Vandermosten, CFA NYSE: AEON READ THE FULL AEON RESEARCH REPORT We are initiating coverage of AEON Biopharma, Inc. (NYSE: AEON) with a valuation of $2.00 per share. This value is based on our ...

At first, I really just wanted to do something about the single wrinkle on my forehead. Now, a year later, I find myself getting injections in my jawline as well. I am a 38-year-old office worker.

As cosmetic treatments become more common among young adults, Gen Z is weighing the appeal of preventative Botox against its ...

It is the same "glabellar Botox," yet one place charges a few thousand yen while another charges tens of thousands.If the ...

Looking for 'Botox in a bottle'? Read our review of new British brand Dialogue’s skincare, designed with natural anti-ageing ...

The SkinMedica Firm and Tone Body Lotion is a powerful anti-aging product for the body that smoothes and tightens sagging, ...

It might seem like a risky time to buy new stocks. The Fed raised its benchmark rates for the first time in three years in September, and the 10-Year Treasury's 5.3% yield -- its highest level since ...

Nothing beats botox for a smooth appearance, but other products and treatments can address fine lines and wrinkles and ...

Where AbbVie's cliff is behind it, Merck's is still ahead. Keytruda was about $31.6 billion of Merck's $65.0 billion of 2025 sales. Its main U.S. patent expires in December 2028, and Merck expects ...

Could my skin be smoother, fresher and better at 47 than it was when I had the considerable biological advantage of being ten ...